#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Paul Sauer Email
SVP, Development and Manufacturing . Vaxcyte
How to contact Paul Sauer
Join and see Paul's contact info for free!Current Roles
Employees:
323Revenue:
$17.1MAbout
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company's cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte's proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).Vaxcyte Address
825 Industrial RoadFoster City, CA
United States